Introduction
============

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide.[@B1] The incidence of HCC and associated mortality are anticipated to grow in the next decade, particularly in western countries.[@B1] HCC is difficult to treat because its treatments depend on not only tumor stage, but also liver function. Based on official guidelines and clinical practices,[@B2], [@B3] hepatic resection is the main treatment for HCC. However, the success of hepatic resection is largely dependent on the health of the liver, especially the degree of liver cirrhosis, which also affects long-term overall survival after surgery.[@B4]

Nutritional status has been reported to predict perioperative morbidity and mortality after hepatic resection in HCC patients.[@B5], [@B6] Serum albumin level has been routinely used in clinical practice as a surrogate marker to evaluate nutritional status and liver function. Serum albumin concentration is used as an independent mortality risk predictor in a broad range of clinical and research settings.[@B7], [@B8] However, measurement of serum albumin can be inaccurate because the level of serum albumin can be affected by blood transfusion or other factors. Serum prealbumin provides an alternative because its level is less affected by liver diseases, even though it is synthesized by the liver.[@B9] Moreover, serum prealbumin level is a good indicator of nutritional status.[@B9] A few recent studies reported that low preoperative prealbumin level is a negative independent prognostic factor for cancer-specific survival.[@B10], [@B11] However, the relationship between preoperative serum prealbumin level and long-term prognosis in patients with HCC after hepatic resection has not been fully elucidated. Therefore, this retrospective study aimed to investigate the role of preoperative serum prealbumin level on the long-term survival in HCC patients.

Patients and Methods
====================

Medical records were retrospectively examined to identify patients with confirmed hepatic resection and post-operative HCC diagnosis between June 2007 to December 2015 at the Affiliated Tumor Hospital of Guangxi Medical University. Patients were included in this study if they (a) were admitted for initial HCC treatment at our hospital; (b) had no treatment prior to hepatic resection and no other malignancies; (c) were followed-up at our hospital for more than 3 months; (d) had complete clinical data, including serum albumin and prealbumin. This retrospective study was approved by the Ethics Committee of the Hospital.

Hepatic resection and follow-up procedures were described in detail previously.[@B12], [@B13] Clinical stage of HCC was determined according to the guidelines of the European Association for the Study of the Liver Clinical Practice.[@B2] Liver cirrhosis was confirmed by histopathological examination. Follow-up investigations consisted of blood testsfor liver function and alpha-fetoprotein levels, abdominal ultrasonography, computed tomography, or magnetic resonance imaging. Survival time was defined as the interval (in months) from the date of hepatic resection to the date of last follow-up (31 July 2018) or death. Serum prealbumin was measured as part of liver function testing after overnight fasting at 6:00-7:00 a.m. on the second morning of hospitalization. Normal level of serum prealbumin was defined as at 200 mg/L or higher, so this value was used to classify patients as having \"reduced\" or \"normal\" levels. This normal level is based on our hospital\'s experience. Liver function was tested with ADVIA^®^ 2400 Chemistry System (Siemens Healthcare Diagnostics Inc).

Data were analyzed using SPSS 17.0 (IBM, Armonk, NY, USA). Categorical data were presented as frequency and percentage (%). In propensity score analysis, differences between patients with reducedor normal prealbumin were assessed for significance using Pearson chi-square test or Fisher\'s exact test. Survival curves were estimated using Kaplan-Meier method and compared by log rank test. Multivariate analyses were performed using Cox regression proportional hazards model to identify potential risk factors associated with mortality. Subgroup analysis was performed to examine a potential relationship between serum prealbumin level and overall survival for patients with or without liver cirrhosis. Spearman rank-order correlation analysis was used to identify the correlation between albumin and prealbumin levels. Differences were considered significant in all statistical tests when P\<0.05 (two-tailed).

In order to reduce bias in patient selection, propensity score analysis was carried out using logistic regression to create propensity scores for reduced and normal serum prealbumin groups in an observational database. Logistic regression was applied to clinical variables when they differed significantly between reduced and normal groups and propensity scores were generated along a continuous range from 0 to 1. Propensity score model was then used to provide a one-to-one nearest-neighbor match between reduced and normal groups.

Results
=======

Between June 2007 and December 2015, 1780 patients with HCC underwent hepatic resection at our tertiary liver center. Based on inclusion criteria, 1349 (75.8%) patients were included in this study, in which 1168 (86.6%) were male and 181 (13.4%) were female. Among 1349 patients, 649 had normal serum prealbumin levels (≥200 mg/L) and 700 had reduced levels (\<200 mg/L).

Preoperative prealbumin level correlated significantly with age, gender, HCC family history, macrovascular invasion, tumor size, tumor stage, hepatitis B surface antigen, albumin, total bilirubin, Child-Pugh class, and alpha-fetoprotein (Table [1](#T1){ref-type="table"}). Preoperative prealbumin level did not, however, correlate with liver cirrhosis, tumor number, tumor capsule or alanine transaminase (Table [1](#T1){ref-type="table"}). Spearman correlation analysis found positive correlation between preoperative albumin and prealbumin levels (R = 0.494, *P*\< 0.001; Figure [1](#F1){ref-type="fig"}A). Moreover, patients with liver cirrhosis had significantly lower preoperative prealbumin levelsthan those without (*P* = 0.002; Figure [1](#F1){ref-type="fig"}B).

Median length of patient follow-up was 45.3 months. Patients with serum prealbumin ≥200 mg/L showed significantly higher rates of disease-free survival than those with prealbumin \< 200 mg/L at 1 year (65% vs. 49%), 3 years (35% vs. 22%), and 5 years (33% vs. 6%) (*P* \< 0.001, Figure [2](#F2){ref-type="fig"}). Moreover, overall survival rates were significantly higher among patients with serum prealbumin ≥ 200 mg/L than among those with prealbumin \< 200 mg/L at 1year (89% vs. 81%), 3years (72% vs. 59%), and 5years (62% vs. 50%) (*P* \< 0.001, Figure [3](#F3){ref-type="fig"}A). Propensity score analysis showed similar results (*P*\<0.001, Figure [3](#F3){ref-type="fig"}B).

Since levels of serum albumin and prealbumin may reflect the degree of liver cirrhosis, subgroup analysis was performed depending on whether patients had liver cirrhosis or not. We found that reduced prealbumin level was associated with worse overall survival than normal prealbumin, regardless of whether patients had liver cirrhosis (Figure [3](#F3){ref-type="fig"}C) or not (Figure [3](#F3){ref-type="fig"}D).

Discussion
==========

In recent decades, many preoperative clinicopathologic variables were used to predict postoperative liver dysfunction, perioperative mortality, and long-term overall survival, such as serum markers of liver fibrosis,[@B14] splenic thickness,[@B15] neutrophil-to-lymphocyte ratio,[@B16] Controlling Nutritional Status Score,[@B5] body-mass index,[@B17] and age[@B18]. Estimation of hepatic functional reserve in the future remnant liver is critical for HCC patients before hepatic resection.

Both Child-Pugh and albumin-bilirubin scores[@B8], [@B19] include albumin to predict hepatic functional reserve before surgery. However, the level of serum albumin can be affected by supplemental infusion of human serum albumin and blood transfusion. This exogenous albumin persists in the body a long time, which affects the accuracy of liver function estimation because the half-life of albumin is about 20 days.[@B20] Therefore, many studies chose prealbumin as a sensitive marker to predict prognosis because the half-life of prealbumin is only 0.5 day.[@B21] Serum prealbumin level reflects liver protein synthesis and secretion. Therefore, measuring serum prealbumin levels can predict early liver function damage and prognosis of some diseases.[@B22] For example, prealbumin levels have been used as a marker for predicting infectious complications after gastric surgery,[@B23] the risk of recurrent colorectal cancer,[@B24] early recurrence after curative pulmonary resection for non-small-cell lung cancer,[@B25] and postoperative liver insufficiency in hepatic resection patients.[@B26]

The present study examined the ability of preoperative serum prealbumin level to predict overall and disease-free survival after liver resection in a large cohort of HCC patients in a tertiary liver center. We found that preoperative serum prealbumin level may be a useful marker for predicting long-term overall and disease-free survival, in the presence or absence of liver cirrhosis. These findings are consistent with previous studies.[@B27], [@B28] A previous study used a cut-off value of 170 mg/L for preoperative prealbumin level compared to 200 mg/L in the present study. They found only 29% (437/1483) patients with reduced prealbumin level, lower than the 51.9% (700/1349) in the present study.[@B28] Our previous small study used a cut-off value of 182 mg/L for preoperative prealbumin level.[@B27] Other studies found that prealbumin level lower than 170 mg/L is an independent risk factor for hepatic insufficiency after hepatic resection.[@B26], [@B29] In other types of cancers, prealbumin level lower than 220 mg/L is associated with higher rate of recurrence and lower rate of survival in colorectal cancer.[@B24] Prealbumin level of \<230 mg/L has been associated with greater risk of non-small cell carcinoma.[@B25] Therefore, finding an appropriate prealbumin cut-off level for a particular type of cancer is critical for predicting tumor recurrence and patient survival.

A number of conditions are known to affect the level of prealbumin and/or albumin, including liver cirrhosis, hepatitis B/C virus, loss of compensatory liver function, and abnormal nutritional status.[@B28] Liver cirrhosis is one of the decisive factors for liver function, which critically affects prognosis after hepatic resection. Our results showed that HCC patients with liver cirrhosis had lower prealbumin level, which was associated with poorer patient survival. These results support the idea that serum prealbumin level may predict pre-existing liver cirrhosis, which is critical for liver function and therefore prognosis in HCC patients after liver resection.

There are a few limitations in this study. The main drawback is the lack of internal or external validation. However, our previous study with small sample size used a cut-off value of 182 mg/L for preoperative prealbumin level found similar results. Moreover, other study from other province of China also found similar results. Second, patient prealbumin level groups were not assigned randomly. However, propensity score analysis was used in the present study to increase the comparability of the two populations. Third, all study participants came from a single center. Therefore, readers should be cautious that these results may or may not apply to other populations in other regions. Our findings should be verified and extended in larger, multi-center studies.
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Relationships between preoperative prealbumin levels and clinicopathological factors.

  Factor                                    N=1349 (%)    Total population   After propensity scoring                                       
  ----------------------------------------- ------------- ------------------ -------------------------- --------- ------------ ------------ -------
  Age, year                                                                                                                                 
  \>60                                      228 (16.9)    92 (14.2)          136 (19.4)                 0.011     63 (16.5)    51(13.4)     0.264
  ≤60                                       1121 (83.1)   557 (85.8)         564 (80.6)                           318(83.5)    330 (86.6)   
  Gender                                                                                                                                    
  Male                                      1169 (86.7)   595 (91.7)         574 (82.0)                 \<0.001   340 (89.2)   339 (89.0)   1.000
  Female                                    180 (13.3)    54 (8.3)           126 (18.0)                           41 (10.8)    42(11.0)     
  Hepatocellular carcinoma family history                                                                                                   
  Present                                   234 (17.3)    127 (19.6)         107 (15.3)                 0.044     42 (11)      53 (13.9)    0.273
  Absent                                    1115 (82.7)   522 (80.4)         593 (84.7)                           339(89)      328(86.1)    
  Cirrhosis                                                                                                                                 
  No                                        597 (44.3)    298 (45.9)         299 (42.7)                 0.249     161 (42.3)   156 (40.9)   0.769
  Yes                                       752 (55.7)    351 (54.1)         401 (57.3)                           220 (57.7)   225 (59.1)   
  Macrovascular invasion                                                                                                                    
  No                                        1094 (80.4)   559 (86.1)         535 (76.4)                 \<0.001   310 (81.4)   312 (81.9)   0.926
  Yes                                       255 (19.6)    90 (13.9)          165 (23.6)                           71 (18.6)    69 (18.1)    
  Tumor number                                                                                                                              
  ≤3                                        1274 (94.4)   614 (94.6)         660 (94.3)                 0.813     367 (96.3)   363 (95.3)   0.589
  \>3                                       75 (5.6)      35 (5.4)           40 (5.7)                             14 (3.7)     18 (4.7)     
  Tumor size, cm                                                                                                                            
  ≤5                                        533 (39.5)    326 (50.2)         207 (29.6)                 \<0.001   141 (37.0)   145 (38.1)   0.822
  \>5                                       816 (60.5)    323 (49.8)         493 (70.4)                           240 (63.0)   236 (61.9)   
  Barcelona Clinic Liver Cancer Stage                                                                                                       
  0/A                                       862 (63.9)    445 (68.6)         417 (59.6)                 \<0.001   246 (64.6)   255 (66.9)   0.672
  B                                         214 (15.9)    108 (16.6)         106 (15.1)                           64 (16.8)    55 (14.5)    
  C                                         273 (20.2)    96 (14.8)          177 (25.3)                           71 (18.6)    71 (18.6)    
  Tumor capsule                                                                                                                             
  Complete                                  889 (65.9)    437 (67.3)         452 (64.6)                 0.301     248 (65.1)   248 (65.1)   1.000
  Incomplete                                460 (34.1)    212 (32.7)         248 (35.4)                           133 (34.9)   133 (34.9)   
  Hepatitis B surface antigen                                                                                                               
  Negative                                  181 (13.4)    111 (17.1)         70 (10.0)                  \<0.001   47 (12.3)    37 (9.7)     0.298
  Positive                                  1169 (86.6)   538 (82.9)         630 (90.0)                           334 (87.7)   344 (90.3)   
  Albumin, g/L                                                                                                                              
  ≤35                                       121 (9.0)     11 (1.7)           110 (15.7)                 \<0.001   9 (2.4)      11 (2.9)     0.821
  \>35                                      1228 (91.0)   638 (98.3)         590 (84.3)                           372 (97.6)   370 (97.1)   
  Alanine transaminase, U/L                                                                                                                 
  ≤40                                       816 (60.5)    397 (61.2)         419 (59.9)                 0.656     229 (60.1)   226 (59.3)   0.883
  \>40                                      533 (39.5)    252 (38.8)         281 (40.1)                           152 (39.9)   155 (40.7)   
  Total bilirubin, μmol/L                                                                                                                   
  ≤21                                       1220 (90.4)   607 (93.5)         613 (87.6)                 \<0.001   353 (92.7)   350 (91.9)   0.787
  \>21                                      129 (9.6)     42 (6.5)           87 (12.4)                            28 (7.3)     31 (8.1)     
  Child-Pugh class                                                                                                                          
  A                                         1245 (92.3)   609 (93.8)         636 (90.9)                 \<0.001   379 (99.5)   379 (99.5)   1.000
  B                                         104 (7.7)     40 (6.2)           64 (9.1)                             2 (0.5)      2 (0.5)      
  Alpha fetoprotein, ng/mL                                                                                                                  
  ≤400                                      770 (57.1)    393 (60.6)         377 (53.9)                 0.015     225 (59.1)   231 (60.6)   0.712
  \>400                                     578 (42.9)    256 (39.4)         322 (46.1)                           156 (40.9)   150 (39.4)   

Data are n (%). pALB, prealbumin.
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